BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Esmat G, Elbaz T, El Raziky M, Gomaa A, Abouelkhair M, Gamal El Deen H, Sabry A, Ashour M, Allam N, Abdel-hamid M, Nada O, Helmy S, Abdel-maguid H, Colonno R, Brown N, Ruby E, Vig P, Waked I. Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. Journal of Hepatology 2018;68:53-62. [DOI: 10.1016/j.jhep.2017.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Hefnawy M, Hammad S, Kadi A, Alsaif N, Mohammed M, Al-hossaini A, Bin Jardan Y, Attwa M, Abou-el-alamin M. Effective quantification of ravidasvir (an NS5A inhibitor) and sofosbuvir in rat plasma by validated LC-MS/MS method and its application to pharmacokinetic study. Arabian Journal of Chemistry 2020;13:8160-71. [DOI: 10.1016/j.arabjc.2020.09.048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Kaddah MMY, Talaat W, El Demellawy MA. Determination and structural characterization of ravidasvir metabolites by LC coupled to triple quadrupole linear ion trap MS: Application to pharmacokinetics and phase I metabolism in rats. Biomed Chromatogr 2021;35:e5146. [PMID: 33893663 DOI: 10.1002/bmc.5146] [Reference Citation Analysis]
3 Andrieux-Meyer I, Tan SS, Thanprasertsuk S, Salvadori N, Menétrey C, Simon F, Cressey TR, Said HRHM, Hassan MRA, Omar H, Tee HP, Chan WK, Kumar S, Thongsawat S, Thetket K, Avihingsanon A, Khemnark S, Yerly S, Ngo-Giang-Huong N, Siva S, Swanson A, Goyal V, Bompart F, Pécoul B, Murad S. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Lancet Gastroenterol Hepatol 2021;6:448-58. [PMID: 33865507 DOI: 10.1016/S2468-1253(21)00031-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Borgia G, Scotto R, Buonomo AR. An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy. Expert Opin Investig Drugs 2019;28:395-7. [PMID: 30943797 DOI: 10.1080/13543784.2019.1602766] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Jones CR, Flower BF, Barber E, Simmons B, Cooke GS. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res 2019;4:132. [PMID: 31754636 DOI: 10.12688/wellcomeopenres.15411.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
6 Hefnawy M, Al-Shehri M, Al-Rashood S, Hammad S, Alanazi M, Alsaif N, Mohammed M, Obaidullah A, El-Gendy M. Validated Microwell-Based Spectrofluorimetric Method for Quantification of Ravidasvir (New Anti-Chronic Hepatitis C Virus-GT4) in Rat Plasma and Its Application to Pharmacokinetic Study. Drug Des Devel Ther 2020;14:4377-85. [PMID: 33116422 DOI: 10.2147/DDDT.S237949] [Reference Citation Analysis]
7 Hellard M, Pedrana A, Draper B. Affordable treatment and political commitment are crucial to eliminate hepatitis C globally. Lancet Gastroenterol Hepatol 2021;6:414-6. [PMID: 33865506 DOI: 10.1016/S2468-1253(21)00135-7] [Reference Citation Analysis]